Malin Corporation plc

Malin invests in and supports highly innovative life sciences companies developing exceptional science and technology.

[Malin Corporation plc @Malin_plc]

Malin has announced a proposal to return up to €80 million of capital to shareholders by way of a tender offer, bringing total capital returns in 2021 to over €95 million. Find out more at: https://t.co/nmwu2NhcT2

#capitalreturns #tenderoffer #lifesciences #biotech

[Malin Corporation plc @Malin_plc]

Encouraging data update today from @PoseidaThera on its CAR-T product candidate for the treatment of metastatic castrate-resistant #prostatecancer at the 6th Annual CAR-TCR Summit.

[Malin Corporation plc @Malin_plc]

Exciting news from the team @PoseidaThera as the company's first #allogeneic #CARTcell product candidate for the treatment of relapsed / refractory #multiplemyeloma receives Investigational New Drug clearance from the US FDA.

[Malin Corporation plc @Malin_plc]

Great news from the team @Immunocore this week with the acceptance of a Biologics License Application for review by the FDA for the company's pioneering therapy for uveal melanoma.

[Immunocore @Immunocore]

We are delighted to announce that @US_FDA has accepted for review a Biologics License Application for an investigational therapy in the treatment of uveal melanoma. More: https://t.co/z5T8Jz6GzP

[Malin Corporation plc @Malin_plc]

Malin has published its 2021 Interim Report today. Click on the link below to read more on the exciting progress made in the first half of 2021, including the sale of investee companies, Kymab and Altan.

https://t.co/uKdqdNqZfg

[Malin Corporation plc @Malin_plc]

Malin is delighted to announce that its subsidiary investee company, Altan Pharma, is to be acquired by @Ethypharm. Malin will receive ~€68 million from the sale of Altan in what is another significant milestone for the company in 2021.

[Malin Corporation plc @Malin_plc]

Delighted to announce the completion of the sale of @KymabLtd to @sanofi.

Read more: https://t.co/N9fRedPFDn

#innovation #drugdevelopment #biotech #acquisition

[Malin Corporation plc @Malin_plc]

Malin announced 2020 Full Year Results this morning with the fair value estimate of investee companies increasing to €449 million at 19 March 2021.

Read the full press release here: https://t.co/7hdvpxuef7

#healthcare #LifeSciences

[Malin Corporation plc @Malin_plc]

More great developments @Immunocore with the FDA awarding Breakthrough Therapy Designation for #tebentafusp for the treatment of certain HLA-A*02:01-positive adult patients #uvealmelanoma #immunotherapy

[Immunocore @Immunocore]

We are pleased to announce that the @US_FDA granted Breakthrough Therapy Designation (BTD) for #tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic #uvealmelanoma (mUM). See more: https://t.co/gHcT75kpPj

[Malin Corporation plc @Malin_plc]

Looking forward to joining @PoseidaThera for their first virtual R&D Day this afternoon to gain further insight into their exciting next-generation cell & gene therapy technologies #CART #oncology #genetherapy

[Malin Corporation plc @Malin_plc]

Great news from @Immunocore this morning as it prices an upsized @Nasdaq IPO & completes a private placement, raising approximately $273 million. Its ADSs are expected to begin trading today under the ticker symbol "IMCR". Read more here: https://t.co/OXHJfthtwg
#NASDAQ #biotech

[Malin Corporation plc @Malin_plc]

Malin is delighted to announce that its investee company @KymabLtd is to be acquired by Sanofi for total consideration of up to $1.45bn, including an upfront payment of $1.1bn and up to $350mn upon the achievement of certain milestones.

Read more here: https://t.co/6tGJHDdAdh

[Malin Corporation plc @Malin_plc]

We are delighted with today's announcement from @MycoviaPharma of positive topline results from the company's third Phase 3 clinical trial for the treatment of RVVC - congratulations to the Mycovia team!

#rvvc #womenshealth #malin

[Mycovia Pharmaceuticals @MycoviaPharma]

We are proud to announce positive topline results from the Phase 3 ultraVIOLET clinical trial of our lead drug candidate oteseconazole for treatment of patients with #RVVC. Read more here: https://t.co/sBxSpgSitw

[Malin Corporation plc @Malin_plc]

Exciting news from @MycoviaPharma who announced positive topline results from two pivotal Phase 3 VIOLET studies in patients with #RVVC

Read more from our CEO, Darragh Lyons, here: https://t.co/SLzQJjOygu

#womenshealth #drugdevelopment

[Malin Corporation plc @Malin_plc]

"We are very encouraged by the Phase 2a data announced by @KymabLtd today". See more on Kymab's latest clinical development from Darragh Lyons, Malin CEO at: https://t.co/EKbCOsjJeG

[Kymab Ltd @KymabLtd]

Delighted to announce that the primary endpoints in our Phase 2a, randomized, double-blinded, placebo-controlled study have been met https://t.co/04Vv0hDZgq #KY1005 #AtopicDermatitis

[Malin Corporation plc @Malin_plc]

Great news from @PoseidaThera, a Malin Priority Asset, on dosing the first patient in the company's Phase 1 clinical trial evaluating P-PSMA-101, a solid tumour CAR-T candidate.

[Malin Corporation plc @Malin_plc]

Great to see @XenexDisinfect announcing its LightStrike™ pulsed xenon disinfection robot has been proven to deactivate SARS-CoV-2, the virus that causes #Covid_19, in only two minutes.

Click here to find out more: https://t.co/WD7Jzncbvm

[Malin Corporation plc @Malin_plc]

Malin has published its full year results and 2019 annual report this morning.

See full press release here: https://t.co/HK7BvCzCcr

[Malin Corporation plc @Malin_plc]

Malin will report its Full Year 2019 Results and publish its 2019 Annual Report on Wednesday, 25 March 2020. Darragh Lyons, CEO, will host conference call for analysts and investors at 11:00am GMT on the day of publication.

For more information visit: https://t.co/hEJLX0kreU

[Malin Corporation plc @Malin_plc]

Malin is delighted to announce the sale of @3D4Medical , an award-winning 3D medical technology company and Malin Growth Potential Asset, to @ElsevierConnect, a global leader in anatomy education and content. Read more about this transaction here: https://t.co/FsEB7hnhqj